Skip to main content
This section has no specific content
You will be redirected to the website of ROVI Spain in 5 seconds, where we will expand the information requested.
ACCESS
NO ACCESS
This section has no specific content
You will be redirected to the website of ROVI Spain in 5 seconds, where we will expand the information requested.
ACCESS
NO ACCESS
This section has no specific content
You will be redirected to the website of ROVI Spain in 5 seconds, where we will expand the information requested.
ACCESS
NO ACCESS
ROVI Subsidiaries
Spain
France
Italy
Germany
Poland
Portugal
United Kingdom
Ethics channel
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Enoxaparin Biosimilar
Contact
Products
Hospital Products
Diagnostic Products
OTC Products
Manufacturing
Contract manufacturing
Own product Manufacturing
R&D
Pipeline
ISM
Glycomics
Multilayer technologies
Shareholders and Investors
General information on the Company
How to contact the Company
Shares and share capital
Investor Agenda
Dividends
Public offerings and admission to trading
Public tender offers
Bylaws
Relevant events
Shareholders agreements
Significant interests and treasury shares
Analyst Coverage
Financial and economic information
Audit Report, Audited Annual Financial Statements (individual and consolidated), Management Report and Annual Report
Regular Public Information
Public information sent to regulatory bodies, other than information prepared under Spanish regulations
Rating
Average payment period to suppliers
Share Evolution
Stock Market History
Economic information
Share Value
Corporate Governance
Regulations of the Shareholders Meeting
General Shareholders' Meeting: exercising the right to information
Notice and Agenda of the Meeting
Shareholders request for information or clarification
Proxy voting
Distance voting at General Meetings
Information on the contents of past General Meetings
Board of Directors
Regulations of the Board of Directors
Annual Corporate Governance Report
Director compensation
Board Committees
Corporate Policies
Full texts of the proposed resolutions to be taken and the documentation available to the shareholder prior to the Meeting
Internal rules of conduct relating to trading in the securities market
Contact
Information for Investors
Annual Reports
Press Releases
Information for investors
Webcasts and other presentations
Contact
CSR
Mission, vision and values
Relations with Stakeholders
Commitment to Society
Commitment to the environment
Commitment to the employees
Media
FAQS
News
Contact
Work with Us
INTRANET
Home
Contact
News
News
Find out more …
FAQs
News
Contact
Filtrar resultados
Año
Year
-Year
2021
2022
2023
2024
2025
2026
2027
Desde
Date
E.g., 11/24/2024
Hasta
Date
E.g., 11/24/2024
29/04/2014
2014 first quarter results press release
153i.pdf
27/02/2014
Full year 2013 results press release
151i.pdf
27/02/2014
Full year 2013 results presentation
152i.pdf
27/11/2013
ROVI announces the exclusive commercialization of Medikinet y Medicebran in Spain
149i.pdf
26/11/2013
ROVI announces the agreement to market Hirobriz Breezhaler y Ulunar Breezhaler en España
148i.pdf
07/11/2013
Nine-month period ended 30 September 2013 results press release
145i.pdf
07/11/2013
Nine-month period ended 30 September 2013 results presentation
146i.pdf
31/07/2013
2013 first half results presentation
144i.pdf
31/07/2013
2013 first half results press release
143i.pdf
06/06/2013
ROVI exercises the Purchase Option over Rhodogil
142i.pdf
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »